Premium
Probable association between duloxetine, acute angle‐closure glaucoma
Author(s) -
Lam Y. W. Francis
Publication year - 2014
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30003
Subject(s) - duloxetine , medicine , depression (economics) , glaucoma , reuptake inhibitor , serotonin reuptake inhibitor , neuropathic pain , anesthesia , serotonin , ophthalmology , alternative medicine , receptor , pathology , economics , macroeconomics
Duloxetine is a serotonin‐norepinephrine reuptake inhibitor (SNRI) approved for the management of major depression as well as diabetic peripheral neuropathic pain. Although SNRIs and selective serotonin reuptake inhibitors (SSRIs) have good safety profiles, there have been reports of acute angle‐closure glaucoma associated with their use. The following report describes an elderly female who developed ocular side effects two days after receiving duloxetine for management of low back pain and polyneuropathy.1